To date, ZIC2 over-expression was reported to impact the clinical course and prognosis of patients harboring ovarian cancer [18], endometrial cancer [19] and oral squamous cell carcinoma [20], while the molecular mechanism of disease progression was not revealed. This evidence concerns the gene ZIC2 and endometrial cancer.